Previous close | 14.40 |
Open | 17.15 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 42.50 |
Expiry date | 2025-03-21 |
Day's range | 14.40 - 17.15 |
Contract range | N/A |
Volume | |
Open interest | N/A |
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Pfizer Inc (NYSE:PFE) is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform under the brand “Pfizer for All.” The move, reflected in a recent trademark application, aims to provide medical information, mail-order pharmacy, and telehealth services to US patients. Recent reports indicate Pfizer’s intention to include various medications, including its COVID antiviral Paxlovid and diagnostic kits, on the platform later this year, e
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.